What is the current valuation of the US IBS treatment market as of 2024?

The US IBS treatment market was valued at approximately $1328.61 Million in 2024. Read More

What is the projected market valuation for the US IBS treatment market in 2035?

The projected valuation for the US IBS treatment market in 2035 is expected to reach $2337.51 Million. Read More

What is the expected CAGR for the US IBS treatment market during the forecast period 2025 - 2035?

The expected CAGR for the US IBS treatment market during the forecast period 2025 - 2035 is 5.27%. Read More

What are the main segments of the US IBS treatment market?

The main segments of the US IBS treatment market include Medications, Dietary Supplements, Probiotics, and Psychological Therapies. Read More

How much revenue did the Medications segment generate in 2024?

The Medications segment generated revenue between $600.0 Million and $1100.0 Million in 2024. Read More

What is the revenue range for Antispasmodics in the US IBS treatment market?

The revenue range for Antispasmodics in the US IBS treatment market is between $300.0 Million and $550.0 Million. Read More

What routes of administration are utilized in the US IBS treatment market?

The routes of administration in the US IBS treatment market include Oral, Injectable, and Topical. Read More

What is the revenue range for the Pediatric patient type in the US IBS treatment market?

The revenue range for the Pediatric patient type in the US IBS treatment market is between $268.61 Million and $387.51 Million. Read More

What is the expected growth trend for the US IBS treatment market in the coming years?

The US IBS treatment market is likely to experience steady growth, with a projected valuation increase to $2337.51 Million by 2035. Read More

US IBS Treatment Market

Q: Which companies are considered key players in the US IBS treatment market?

Key players in the US IBS treatment market include AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical, GSK, AstraZeneca, Pfizer, Novartis, Bristol-Myers Squibb, and Sanofi. Read More

ID: MRFR/Pharma/17496-HCR 100 Pages Rahul Gotadki Last Updated: September 10, 2026

US IBS Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Medications, Dietary Supplements, Probiotics, Psychological Therapies), By Drug Class (Antispasmodics, Laxatives, Antidiarrheal Agents, Antidepressants), By Route of Administration (Oral, Injectable, Topical) and By Patient Type (Adult, Pediatric) - Growth Outlook & Industry Forecast 2025 To 2035

US IBS Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.27%

2024 Market Size$ 1,328.61 Million

2025 Market Size$ 1,398.62 Million

2035 Market Size$ 2,337.51 Million

Key Players

AbbVie

Boehringer Ingelheim

Takeda Pharmaceutical

GSK

AstraZeneca

Pfizer

Trends

Rise of Personalized Medicine
Increased Focus on Dietary Interventions
Integration of Digital Health Solutions

Opportunities

Growing Prevalence of IBS
Increased Focus on Gut Health
Rising Awareness and Education

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
  1. 4.1.1 Medications
  2. 4.1.2 Dietary Supplements
  3. 4.1.3 Probiotics
  4. 4.1.4 Psychological Therapies
2. 4.2 Security, Access Control and Robotics, BY Drug Class (USD Million)
  1. 4.2.1 Antispasmodics
  2. 4.2.2 Laxatives
  3. 4.2.3 Antidiarrheal Agents
  4. 4.2.4 Antidepressants
3. 4.3 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Topical
4. 4.4 Security, Access Control and Robotics, BY Patient Type (USD Million)
  1. 4.4.1 Adult
  2. 4.4.2 Pediatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GSK (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY PATIENT TYPE
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PATIENT TYPE, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US IBS Treatment Market Segmentation

US IBS Treatment Market By Type (USD Million, 2025-2035)

Medications
Dietary Supplements
Probiotics
Psychological Therapies

US IBS Treatment Market By Drug Class (USD Million, 2025-2035)

Antispasmodics
Laxatives
Antidiarrheal Agents
Antidepressants

US IBS Treatment Market By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Topical

US IBS Treatment Market By Patient Type (USD Million, 2025-2035)

Adult
Pediatric

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”